Lesopitron

Lesopitron
Systematic (IUPAC) name
2-{4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]piperazin-1-yl}pyrimidine
Clinical data
Legal status
  • Uncontrolled
Routes of
administration		 Oral
Identifiers
CAS Number 132449-46-8
ATC code None
PubChem CID 60813
ChemSpider 54801
UNII H1CGM4755H YesY
Chemical data
Formula C15H21ClN6
Molar mass 320.82 g/mol

Lesopitron (E-4424) is a selective full agonist of the 5-HT1A receptor which is structurally related to the azapirones.[1] In 2001 it was under development by Esteve as an anxiolytic for the treatment of generalized anxiety disorder (GAD).[2][3] It made it to phase II clinical trials but was apparently discontinued as no new information on lesopitron has surfaced since.[2][3]

See also

References

  1. ↑ Haj-Dahmane S, Jolas T, Laporte AM, et al. (April 1994). "Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat". European Journal of Pharmacology 255 (1-3): 185–96. doi:10.1016/0014-2999(94)90097-3. PMID 8026543.
  2. 1 2 Micheli F (February 2001). "Lesopitron (Esteve)". IDrugs : the Investigational Drugs Journal 4 (2): 218–24. PMID 16032484.
  3. 1 2 Fresquet A, Sust M, Lloret A, et al. (February 2000). "Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder". The Annals of Pharmacotherapy 34 (2): 147–53. doi:10.1345/aph.19041. PMID 10676820.


This article is issued from Wikipedia - version of the Tuesday, September 01, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.